CCL2 and cancer: Further studies found that TαT using single-domain antibodies increased the production of cancer-fighting substances, such as interferon-γ, C-C motif chemokine ligand 5, granulocyte–macrophage colony-stimulating factor, and monocyte chemoattractant protein-1, in the blood and boosted the body’s own anti-cancer immune response in the tumor environment [119].